Global Heart Failure Drugs Market Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 with Novartis, GSK, AstraZeneca, Bayer, and Pfizer Dominating
DUBLIN, May 20, 2019 /PRNewswire/ -- The "Global Heart Failure Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Global Heart Failure Drugs Market will grow at a CAGR of 9.1% during the forecast period
The market has witnessed good growth in the past few years and is sustaining due to the increasing elderly population and increasing prevalence of cardiovascular diseases.
The growing market trend continues and is one of the progressively accepted markets in many countries worldwide. Heart failure drugs manufacturers are concentrating on the procurement of funds and collaborating with universities to expand their R&D capabilities. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.
According to the author's analysis, North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and the availability of a wide range of drugs.
By Drug Class:
-- ACE Inhibitors
-- Angiotensin Receptor Blockers
-- Beta Blockers
-- Diuretics
-- Others
The diuretics segment occupied the largest share in 2018. The existing guiding principle by the American College of Cardiology and the American Heart Association recommends that diuretics should be directed at doses adequate to attain optimum volume station and release cramming without making an extremely fast drop in intravascular capacity.
By Regions:
-- North America
-- Europe
-- APAC
-- RoW
North America is dominant in the global heart failure drugs market followed by Europe. The Duke University in North Carolina, US in collaboration with National Heart, Lung, Blood Institute (NHLBI) and Yale University is conducting phase III clinical trial TRANSFORM-HF a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as a treatment for heart failure.
Heart Failure Drugs Market Research Competitive Analysis - The market is growing at a steady rate with a CAGR of 9.1% during the forecast period 2019-2025. Merger and acquisition, product launches, and strategic collaborations are some of the major strategies adopted by market leaders to maintain their leadership position in the market. For example, in February 2019, Amgen, Cytokinetics, and Servier initiated the METEORIC-HF, the second phase III clinical trial of omecamtiv mecarbil in patients with heart failure.
Universities and educational institutions are collaborating with the market players to develop effective drugs for the treatment of heart failure. For instance, Yale University in collaboration with Boehringer Ingelheim is currently conducting a phase II clinical study; a minor pilot proof of concept study to not only prove the existence but also probe the mechanisms that are fundamental for the cardio-renal effects of empagliflozin in patients with heart failure.
Key Vendors:
-- Novartis AG
-- GlaxoSmithKline PLC
-- AstraZeneca PLC
-- Bayer AG
-- Pfizer, Inc.
Key Competitive Facts
Sclnow Biotechnology Co., Ltd. is studying to access the safety and efficiency of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating individuals suffering from heart failure. This treatment is in phase 1/2 currently.
In January 2019, Sanofi and MyoKardia ended their heart disease drug collaboration.
Market Characteristics
Guidelines Summary
Market Dynamics
Drivers
-- Increasing elderly population
-- Increasing incidence of cardiovascular devices across the globe
Restraints
-- Complex drug development process
-- Adverse effects of heart failure drugs
Opportunities
-- Market expansion opportunities in emerging nations
-- Novel heart failure medicines to fill the gap of unmet need in treatment
Vendors Profile
-- Novartis AG
-- GlaxoSmithKline plc
-- Bayer AG
-- Astra Zeneca PLC
-- Pfizer, Inc.
Companies to Watch for
-- Merck & Co
-- Boehringer Ingelheim GMBH
-- Bristol-Myers Squibb
-- Mylan N.V.
-- Sanofi
-- Amgen Inc.
For more information about this report visit https://www.researchandmarkets.com/r/700pf1
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
